B.Riley Reiterates Buy Rating on TG Therapeutics (TGTX)

February 4, 2026 6:51 AM EST Send to a Friend
B.Riley analyst Mayank Mamtani reiterated a Buy rating and $55.00 price target on TG Therapeutics (NASDAQ: TGTX).The analyst comments "Briumvi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login